Overview

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

Status:
Completed

Trial end date:
2017-12-06

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Atorvastatin
Atorvastatin Calcium
Evolocumab